close
close

Pentixapharm adds strategic acquisition to pipeline | Pharmaceuticals | The Pharmaletter

Posted on by darion

Pentixapharm has announced the acquisition of the pharmaceutical discovery division of another German company, Glycotope.

This strategic move includes a portfolio of preclinical antibodies, laboratories, cell banks, a database of tumor targets, and the necessary equipment for radiopharmaceutical development.

This acquisition will not only significantly strengthen Pentixapharm’s intellectual property and double the number of development projects, but will also expand business and clinical development opportunities.

This article is available to registered users. To continue reading, register for free. A free trial gives you access to exclusive features, interviews, summaries, and commentary from the brightest minds in the pharmaceutical and biotech industry for one week. If you are already a registered user, log in. If your trial has expired, you can sign up here.

Log in to your account

Become a subscriber

820 pounds

Or £77 per month

Sign up now

  • Unlimited access to the best pharmaceutical and biotechnology industry news, commentary and analysis.
  • News on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulation, patents and legal matters, executive appointments, commercial strategy and financial results.
  • Daily summary of the most important events in the pharmaceutical and biotechnology industry.
  • Monthly, in-depth coverage of board appointments and M&A news.
  • Choose an economical annual plan or a flexible monthly subscription

Pharma Letter is an incredibly useful and valuable Life Sciences service that collects daily updates on human and product performance. It’s part of the key information that keeps me up to date

Chairman, Sanofi Aventis UK